EHealth Research Development vs Selling General Administrative Analysis
EHTH Stock | USD 5.65 0.15 2.73% |
EHealth financial indicator trend analysis is much more than just examining eHealth latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether eHealth is a good investment. Please check the relationship between EHealth Research Development and its Selling General Administrative accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in eHealth. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in EHealth Stock please use our How to Invest in EHealth guide.
Research Development vs Selling General Administrative
Research Development vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of eHealth Research Development account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.
The correlation between EHealth's Research Development and Selling General Administrative is 0.8. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of eHealth, assuming nothing else is changed. The correlation between historical values of EHealth's Research Development and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of eHealth are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Research Development i.e., EHealth's Research Development and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.8 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Research Development
Selling General Administrative
Most indicators from EHealth's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into eHealth current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in eHealth. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in EHealth Stock please use our How to Invest in EHealth guide.As of now, EHealth's Tax Provision is decreasing as compared to previous years. The EHealth's current Sales General And Administrative To Revenue is estimated to increase to 0.35, while Selling General Administrative is projected to decrease to under 46.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 536.2M | 403.7M | 451.1M | 473.7M | Total Revenue | 538.2M | 405.4M | 452.9M | 475.5M |
EHealth fundamental ratios Correlations
Click cells to compare fundamentals
EHealth Account Relationship Matchups
High Positive Relationship
High Negative Relationship
EHealth fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 741.6M | 1.0B | 1.1B | 1.1B | 1.1B | 1.2B | |
Total Stockholder Equity | 527.2M | 837.6M | 982.1M | 914.2M | 904.1M | 949.3M | |
Retained Earnings | 271.9M | 316.2M | 193.2M | 73.8M | 7.3M | 6.9M | |
Other Assets | 421.3M | 603.1M | 690.3M | 648.2M | 202.9M | 147.4M | |
Common Stock Shares Outstanding | 24.5M | 27.0M | 26.8M | 27.4M | 28.0M | 21.4M | |
Liabilities And Stockholders Equity | 741.6M | 1.0B | 1.1B | 1.1B | 1.1B | 1.2B | |
Other Stockholder Equity | (16.7M) | 521.0M | 555.9M | 577.2M | 598.8M | 628.7M | |
Total Liab | 214.5M | 202.5M | 167.2M | 198.4M | 209.3M | 219.7M | |
Other Current Liab | 81.1M | 36.8M | 50.6M | 40.9M | 57.2M | 60.1M | |
Total Current Liabilities | 113.0M | 84.4M | 75.5M | 60.6M | 78.5M | 40.2M | |
Other Liab | 67.2M | 76.7M | 55.9M | 37.5M | 43.1M | 22.7M | |
Property Plant And Equipment Net | 47.1M | 57.2M | 49.5M | 32.0M | 27.6M | 16.2M | |
Current Deferred Revenue | 2.6M | 308K | 52.8M | 32.4M | (127K) | (120.7K) | |
Net Debt | 15.6M | 2.8M | (40.6M) | (37.6M) | (12.6M) | (13.2M) | |
Accounts Payable | 24.6M | 36.9M | 13.8M | 6.7M | 7.2M | 7.6M | |
Cash | 23.5M | 43.8M | 81.9M | 144.4M | 115.7M | 85.4M | |
Non Current Assets Total | 533.5M | 709.0M | 741.7M | 711.5M | 731.0M | 767.5M | |
Non Currrent Assets Other | 21.4M | 603.1M | 690.3M | 612.6M | 679.8M | 713.8M | |
Cash And Short Term Investments | 23.5M | 93.4M | 123.2M | 144.4M | 121.7M | 97.3M | |
Net Receivables | 176.9M | 221.0M | 260.6M | 245.4M | 922.2M | 968.3M | |
Common Stock Total Equity | 35K | 38K | 39K | 40K | 46K | 29.8K | |
Non Current Liabilities Total | 101.5M | 118.1M | 91.7M | 137.8M | 130.7M | 137.3M | |
Other Current Assets | 2.4M | 16.7M | 23.8M | 11.3M | 8.6M | 6.1M | |
Property Plant And Equipment Gross | 47.1M | 57.2M | 49.5M | 32.0M | 38.8M | 40.7M | |
Total Current Assets | 208.1M | 331.0M | 407.6M | 401.1M | 382.4M | 401.5M | |
Accumulated Other Comprehensive Income | 116K | 350K | 390K | (73K) | (82K) | (77.9K) | |
Short Term Debt | 4.8M | 10.4M | 11.1M | 13.0M | 14.1M | 11.2M | |
Intangible Assets | 10.1M | 8.6M | 1.9M | 31.3M | 23.6M | 24.8M | |
Common Stock | 35K | 38K | 39K | 40K | 41K | 30.5K | |
Property Plant Equipment | 10.5M | 14.6M | 49.5M | 5.5M | 6.3M | 9.4M | |
Short Long Term Debt Total | 39.1M | 46.6M | 41.4M | 106.8M | 103.2M | 53.8M | |
Inventory | 5.5M | 16.1M | 22.9M | 1.0 | 0.9 | 0.86 | |
Net Tangible Assets | 511.2M | 830.1M | 747.6M | 914.2M | 1.1B | 1.1B | |
Retained Earnings Total Equity | 271.9M | 316.2M | 193.2M | 73.8M | 84.9M | 101.3M | |
Capital Surpluse | 455.2M | 721.0M | 755.9M | 777.2M | 893.8M | 472.6M | |
Deferred Long Term Liab | 64.1M | 72.3M | 50.8M | 32.4M | 37.2M | 26.0M |
Currently Active Assets on Macroaxis
When determining whether eHealth offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of EHealth's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ehealth Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ehealth Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in eHealth. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in EHealth Stock please use our How to Invest in EHealth guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Insurance Brokers space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EHealth. If investors know EHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EHealth listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.108 | Earnings Share (2.62) | Revenue Per Share 16.016 | Quarterly Revenue Growth (0.1) | Return On Assets (0.01) |
The market value of eHealth is measured differently than its book value, which is the value of EHealth that is recorded on the company's balance sheet. Investors also form their own opinion of EHealth's value that differs from its market value or its book value, called intrinsic value, which is EHealth's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EHealth's market value can be influenced by many factors that don't directly affect EHealth's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EHealth's value and its price as these two are different measures arrived at by different means. Investors typically determine if EHealth is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EHealth's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.